Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin.

Zemp FJ, Lun X, McKenzie BA, Zhou H, Maxwell L, Sun B, Kelly JJ, Stechishin O, Luchman A, Weiss S, Cairncross JG, Hamilton MG, Rabinovich BA, Rahman MM, Mohamed MR, Smallwood S, Senger DL, Bell J, McFadden G, Forsyth PA.

Neuro Oncol. 2013 Jul;15(7):904-20. doi: 10.1093/neuonc/not035. Epub 2013 Apr 12.

2.

In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA.

Neuro Oncol. 2015 Aug;17(8):1086-94. doi: 10.1093/neuonc/nou359. Epub 2015 Jan 20.

3.

Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo.

Ogbomo H, Zemp FJ, Lun X, Zhang J, Stack D, Rahman MM, McFadden G, Mody CH, Forsyth PA.

PLoS One. 2013 Jun 10;8(6):e66825. doi: 10.1371/journal.pone.0066825. Print 2013.

4.

Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin.

Lun X, Alain T, Zemp FJ, Zhou H, Rahman MM, Hamilton MG, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2010 Jan 15;70(2):598-608. doi: 10.1158/0008-5472.CAN-09-1510. Epub 2010 Jan 12.

5.

Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.

Weng M, Gong W, Ma M, Chu B, Qin Y, Zhang M, Lun X, McFadden G, Forsyth P, Yang Y, Quan Z.

Mol Cancer. 2014 Apr 13;13:82. doi: 10.1186/1476-4598-13-82.

6.

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin.

Lun XQ, Zhou H, Alain T, Sun B, Wang L, Barrett JW, Stanford MM, McFadden G, Bell J, Senger DL, Forsyth PA.

Cancer Res. 2007 Sep 15;67(18):8818-27.

7.

Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.

Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.

Clin Cancer Res. 2014 Nov 15;20(22):5756-67. doi: 10.1158/1078-0432.CCR-13-3389. Epub 2014 Oct 14.

8.

On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.

Stechishin OD, Luchman HA, Ruan Y, Blough MD, Nguyen SA, Kelly JJ, Cairncross JG, Weiss S.

Neuro Oncol. 2013 Feb;15(2):198-207. doi: 10.1093/neuonc/nos302. Epub 2012 Dec 21.

9.

M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma.

Pisklakova A, McKenzie B, Zemp F, Lun X, Kenchappa RS, Etame AB, Rahman MM, Reilly K, Pilon-Thomas S, McFadden G, Kurz E, Forsyth PA.

Neuro Oncol. 2016 Mar 8. pii: now006. [Epub ahead of print]

10.

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, Forsyth PA.

Mol Ther. 2010 Nov;18(11):1927-36. doi: 10.1038/mt.2010.183. Epub 2010 Aug 31.

11.

Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.

Zemp FJ, McKenzie BA, Lun X, Reilly KM, McFadden G, Yong VW, Forsyth PA.

Cancer Res. 2014 Dec 15;74(24):7260-73. doi: 10.1158/0008-5472.CAN-14-0876. Epub 2014 Oct 21.

12.

Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Wakimoto H, Kesari S, Farrell CJ, Curry WT Jr, Zaupa C, Aghi M, Kuroda T, Stemmer-Rachamimov A, Shah K, Liu TC, Jeyaretna DS, Debasitis J, Pruszak J, Martuza RL, Rabkin SD.

Cancer Res. 2009 Apr 15;69(8):3472-81. doi: 10.1158/0008-5472.CAN-08-3886. Epub 2009 Apr 7.

13.

Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.

Xia S, Lal B, Tung B, Wang S, Goodwin CR, Laterra J.

Neuro Oncol. 2016 Apr;18(4):507-17. doi: 10.1093/neuonc/nov171. Epub 2015 Aug 27.

14.

Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Esaki S, Nigim F, Moon E, Luk S, Kiyokawa J, Curry W Jr, Cahill DP, Chi AS, Iafrate AJ, Martuza RL, Rabkin SD, Wakimoto H.

Int J Cancer. 2017 Dec 1;141(11):2348-2358. doi: 10.1002/ijc.30929. Epub 2017 Aug 26.

PMID:
28801914
15.

Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.

Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.

Stem Cells Transl Med. 2012 Apr;1(4):322-32. doi: 10.5966/sctm.2011-0035. Epub 2012 Mar 21.

16.

Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton.

Irwin CR, Favis NA, Agopsowicz KC, Hitt MM, Evans DH.

PLoS One. 2013 Dec 31;8(12):e84134. doi: 10.1371/journal.pone.0084134. eCollection 2013.

17.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.

18.

A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.

Kanai R, Wakimoto H, Martuza RL, Rabkin SD.

Clin Cancer Res. 2011 Jun 1;17(11):3686-96. doi: 10.1158/1078-0432.CCR-10-3142. Epub 2011 Apr 19.

19.

Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.

Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E.

Clin Cancer Res. 2007 Dec 1;13(23):7155-65.

20.

Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity.

Correa RJ, Komar M, Tong JG, Sivapragasam M, Rahman MM, McFadden G, Dimattia GE, Shepherd TG.

Gynecol Oncol. 2012 May;125(2):441-50. doi: 10.1016/j.ygyno.2012.01.048. Epub 2012 Feb 1.

Supplemental Content

Support Center